EnteroBiotix Raises £27M to Revolutionize Gut Microbiome Therapeutics
EnteroBiotix, a Glasgow, Scotland, UK-based clinical-stage biotechnology company, recently announced raising £27M in funding. This funding includes £15.7m of new equity and the conversion of £11.6m of loan notes into equity from investors such as Thairm Bio, Kineticos Life Sciences, and the Scottish National Investment Bank. The round also saw participation from existing investors, including Scottish Enterprise and many private investors of the company. With this new capital injection, EnteroBiotix aims to advance its lead product candidate, EBX-102-02, through a Phase 2 clinical trial for Irritable Bowel Syndrome in collaboration with the Functional Gut Clinic, while also progressing its pipeline for other conditions associated with a disrupted gut microbiome, such as liver cirrhosis and hepatic encephalopathy.
Under the leadership of CEO Dr.
James McIlroy, EnteroBiotix is focused on developing full-spectrum microbial therapeutics for patients facing serious unmet medical needs. The company's product platform is designed to provide tailored, high-diversity microbial products that can fortify and restore the microbiome, thereby addressing critical patient needs. Dr. McIlroy expressed his excitement about the new investment, stating that it will help accelerate the development of their innovative product pipeline and bring them closer to their goal of revolutionizing the standard of care for patients suffering from gut microbiome-related conditions.
Dr. McIlroy emphasized the company's commitment to transforming the standard of care for patients worldwide and expressed gratitude for the support from new partners at the Scottish National Investment Bank and existing investors. EnteroBiotix is looking forward to leveraging this funding to advance their mission of bringing innovative treatments to market and making a positive impact on the lives of patients globally. With a strong vision and dedicated team, EnteroBiotix is poised to drive advancements in the field of microbial therapeutics and improve outcomes for individuals with serious medical conditions.
They've invested in EnteroBiotix
Get to know these Healthtech investors
Click here for a full list of 6,908+ startup investors in the UK